Acer Saccharum Pollen Alnus Rubra Pollen Beef Live
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Acer Saccharum Pollen Alnus Rubra Pollen Beef Live
- Multi-Allergen Extract Mixture: Evaluation Report
Multi-Allergen Extract Mixture: Evaluation Report
Notice: This Evidence Pack contains no TxGNN predicted indications. This report documents the data status and provides recommendations for the next steps before a repurposing evaluation can be conducted.
One-Sentence Summary
This candidate consists of an 18-component allergen/biological mixture — including multiple tree pollens, bovine-derived materials, corticotropin, and histamine dihydrochloride — which is characteristic of allergy immunotherapy or diagnostic scratch-test preparations. The TxGNN model returned no predicted indications for this candidate, and the drug has no registered licenses in Taiwan. Without a DrugBank ID or predicted indications, a full repurposing evaluation cannot be completed at this stage.
Quick Overview
| Item | Content |
|---|---|
| Drug Name (INN) | 18-component allergen mixture (pollen extracts, bovine materials, corticotropin, histamine dihydrochloride) |
| DrugBank ID | Not assigned |
| Original Indication | Not available |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only) — effectively not evaluable |
| Taiwan Market Status | Not marketed (0 licenses) |
| Recommended Decision | Hold |
Why This Case Cannot Be Evaluated Yet
This candidate is a complex multi-component mixture containing 18 distinct ingredients, including:
- Tree pollens (maple, red alder, birch, hazel, European beech, ash, Virginia juniper, London plane, white poplar, English oak, crack willow, elderflower, American elm)
- Animal-derived biologicals (beef liver, bovine adrenal gland)
- Pharmacological reference substances (corticotropin/ACTH, histamine dihydrochloride)
Mixtures of this type are typically found in allergy immunotherapy preparations (allergen desensitisation vaccines) or allergen diagnostic panels used for skin-prick testing. In either case, the “drug” is not a single molecular entity, and standard drug repurposing models like TxGNN — which operate on single-drug nodes in a biomedical knowledge graph — are not designed to process composite allergen extracts.
The absence of a DrugBank ID confirms that this mixture was not resolved to any node in the TxGNN knowledge graph, which explains why no predicted indications were generated.
Data Gaps Blocking Evaluation
The following gaps must be resolved before evaluation can proceed:
| Gap ID | Item | Severity | Impact | Recommended Action |
|---|---|---|---|---|
| DG001 | Package insert warnings / contraindications | Blocking | Cannot complete safety pre-screen | Download PDF from TFDA website |
| DG002 | Mechanism of action (MOA) | High | Cannot perform mechanistic relevance analysis | Query DrugBank API for each active component individually |
| DG003 | DrugBank ID | Blocking | TxGNN cannot generate predictions without a graph node | Map each component separately; corticotropin (DB00741) and histamine (DB04660) are individually registered |
| DG004 | Original approved indication | High | Cannot establish repurposing baseline | Search TFDA / US FDA / EMA for each component or the combined product |
Recommended Path Forward
Because this product is a multi-component mixture, standard single-drug repurposing analysis is not directly applicable. The recommended approach is to decompose the mixture into evaluable components:
- Corticotropin (ACTH) — DrugBank ID DB00741 — has known indications (diagnostic testing, infantile spasms, MS relapse) and is amenable to TxGNN repurposing analysis on its own.
- Histamine dihydrochloride — used as a positive control in allergy testing; limited repurposing relevance, but can be queried separately.
- Pollen and animal-derived allergen components — these are not standard small-molecule drugs; they are biological extracts. Repurposing analysis is not applicable to these components.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model was unable to generate any repurposing predictions for this candidate because the drug is a multi-component allergen mixture without a single DrugBank knowledge-graph node. The Evidence Pack is effectively empty of actionable signals.
To proceed, the following is needed:
- Decompose the mixture: Run separate TxGNN evaluations for corticotropin (DB00741) and histamine dihydrochloride as individual drug candidates.
- Clarify product class: Confirm whether this is an allergen immunotherapy product or a diagnostic reagent, as this determines whether repurposing is conceptually relevant.
- Resolve DG001–DG004: Obtain package insert, MOA data, and original indication for each active component before re-submitting to the pipeline.
- Do not re-run TxGNN on the full 18-component INN string — the composite string will not resolve to a graph node.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.